Phase 3 Studies of Merck's Bezlotoxumab Successful

News   Sep 22, 2015

 
Phase 3 Studies of Merck's Bezlotoxumab Successful
 
 
 

RELATED ARTICLES

Scientists with Novel Approaches to Fighting Cancer Awarded $3M

News

The Damon Runyon Cancer Research Foundation announced that ten scientists with novel approaches to fighting cancer have been named 2018 recipients of the Damon Runyon-Rachleff Innovation Award.

READ MORE

LifeArc and Milner Therapeutics Institute Announce a New Partnership in AI for Target Discovery

News

LifeArc®, the UK-based medical research charity, and the Milner Therapeutics Institute at the University of Cambridge, today announced a new partnership to identify and validate new drug targets in immuno-oncology and respiratory diseases.

READ MORE

Anti-Inflammatory Pill Could Make Vaccines More Effective for the Elderly

News

By identifying why skin immunity declines in old age, a UCL-led research team has found that an anti-inflammatory pill could help make vaccines more effective for elderly people.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE